Genetics & IVF Institute, Inc.

Belkins
Genetics & IVF Institute, Inc (GIVF) is a privately owned, diversified international reproductive sciences company. Founded in 1984, GIVF was the first outpatient fertility center in the United States. GIVF's infertility clinic, prenatal genetics clinic and diagnostics labs as well as its corporate headquarters are located Fairfax, VA.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SOPHIA GENETICS AND IDT PARTNER TO CREATE NGS SOLUTIONS IN ROUTINE CLINICAL DIAGNOSTICS

Integrated DNA Technologies | February 15, 2016

news image

Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today the signing of a new strategic partnership with Integrated DNA Technologies (IDT). Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM™ analytics platform with IDT’s NGS target capture products. The new bundle will create the most advanced NGS data analytics platform in the market. With these bundle solutions, Sophia Genetics will address the needs of European hospitals t...

Read More

SEATTLE GENETICS TO HOST CONFERENCE CALL AND WEBCAST DISCUSSION OF FOURTH QUARTER AND YEAR 2016 FINANCIAL RESULTS

Seattle Genetics | February 09, 2017

news image

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update...

Read More

SEATTLE GENETICS INITIATES PHASE 1 TRIAL OF SGN-CD352A FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Seattle Genetics | January 05, 2017

news image

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called a pyrrolobenzodiazepine (P...

Read More

SEATTLE GENETICS ANNOUNCES CLINICAL HOLD ON SEVERAL PHASE 1 TRIALS OF VADASTUXIMAB TALIRINE (SGN-CD33A)

Seattle Genetics | December 27, 2016

news image

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML)...

Read More
news image

SOPHIA GENETICS AND IDT PARTNER TO CREATE NGS SOLUTIONS IN ROUTINE CLINICAL DIAGNOSTICS

Integrated DNA Technologies | February 15, 2016

Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today the signing of a new strategic partnership with Integrated DNA Technologies (IDT). Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM™ analytics platform with IDT’s NGS target capture products. The new bundle will create the most advanced NGS data analytics platform in the market. With these bundle solutions, Sophia Genetics will address the needs of European hospitals t...

Read More
news image

SEATTLE GENETICS TO HOST CONFERENCE CALL AND WEBCAST DISCUSSION OF FOURTH QUARTER AND YEAR 2016 FINANCIAL RESULTS

Seattle Genetics | February 09, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update...

Read More
news image

SEATTLE GENETICS INITIATES PHASE 1 TRIAL OF SGN-CD352A FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Seattle Genetics | January 05, 2017

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called a pyrrolobenzodiazepine (P...

Read More
news image

SEATTLE GENETICS ANNOUNCES CLINICAL HOLD ON SEVERAL PHASE 1 TRIALS OF VADASTUXIMAB TALIRINE (SGN-CD33A)

Seattle Genetics | December 27, 2016

Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML)...

Read More